Max G. Bronstein is the Senior Director of Health Policy & Corporate Affairs at Audentes Therapeutics. At Audentes, Max leads company interactions with state and federal policymakers and works with various coalitions to advance patient-focused policies for gene therapy and regenerative medicine more broadly. Previously, Max was the Chief Advocacy & Science Policy Officer at the EveryLife Foundation for Rare Diseases where he lead the Foundation’s policy initiatives to close the innovation gap for rare diseases and to enhance newborn screening in America. In 2016, the EveryLife Foundation successfully advocated for the passage of the 21st Century Cures Act and played a key role in advocating for newborn screening legislation in California to help babies with rare diseases. Max has also published in Forbes, Nature, and the New England Journal of Medicine on topics like patient engagement in drug development and the importance of leveraging incentives for closing the innovation gap for rare diseases. Max is the former Director of Science Policy at Research!America and has held various positions in the U.S. government, including at the National Science Foundation, the U.S. House Committee on Science & Technology, and the National Institutes of Health. In 2010, Max founded a non-profit organization, the Journal of Science Policy & Governance, to empower students and young scholars to publish their work. He holds a master’s degree in public policy and a certificate in science and technology policy from the Ford School at the University of Michigan in addition to a BA in biology from Ithaca College, with a minor in writing. When not tormenting Members of Congress, he enjoys hiking around the San Francisco Bay Area and is an avid sailor, swimmer, and SCUBA diver.